| Lael Greenstein, MD | |
|
195 Canal St, Malden, MA 02148-6701 | |
| (781) 338-0500 | |
| Not Available |
| Full Name | Lael Greenstein |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 195 Canal St, Malden, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164867701 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 266386 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nvna And Hospice | Norwell, MA | Home health agency |
| Beth Israel Deaconess Hospital - Milton | Milton, MA | Hospital |
| Cambridge Health Alliance | Cambridge, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Care Of Boston Management Corporation | 6800787714 | 234 |
News Archive
With growing numbers of humans venturing into space, experts predict an increase in the number of people experiencing the physical toll of such travel, including highly common forms of back pain.
The swine flu (H1N1) pandemic has received extensive media coverage this year. The World Health Organization, in addition to providing frequent updates about cases of infection and death tolls, recommends hyper vigilance in daily hygiene such as frequent hand washing or sneezing into the crook of our arms. News reports at all levels, from local school closures to airport screenings and global disease surveillance, continue to remind us of the high risk.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.
› Verified 6 days ago
| Entity Name | Medical Care Of Boston Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437196359 PECOS PAC ID: 6800787714 Enrollment ID: O20040322000778 |
News Archive
With growing numbers of humans venturing into space, experts predict an increase in the number of people experiencing the physical toll of such travel, including highly common forms of back pain.
The swine flu (H1N1) pandemic has received extensive media coverage this year. The World Health Organization, in addition to providing frequent updates about cases of infection and death tolls, recommends hyper vigilance in daily hygiene such as frequent hand washing or sneezing into the crook of our arms. News reports at all levels, from local school closures to airport screenings and global disease surveillance, continue to remind us of the high risk.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.
› Verified 6 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
With growing numbers of humans venturing into space, experts predict an increase in the number of people experiencing the physical toll of such travel, including highly common forms of back pain.
The swine flu (H1N1) pandemic has received extensive media coverage this year. The World Health Organization, in addition to providing frequent updates about cases of infection and death tolls, recommends hyper vigilance in daily hygiene such as frequent hand washing or sneezing into the crook of our arms. News reports at all levels, from local school closures to airport screenings and global disease surveillance, continue to remind us of the high risk.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lael Greenstein, MD 195 Canal St, Malden, MA 02148-6701 Ph: (781) 338-0500 | Lael Greenstein, MD 195 Canal St, Malden, MA 02148-6701 Ph: (781) 338-0500 |
News Archive
With growing numbers of humans venturing into space, experts predict an increase in the number of people experiencing the physical toll of such travel, including highly common forms of back pain.
The swine flu (H1N1) pandemic has received extensive media coverage this year. The World Health Organization, in addition to providing frequent updates about cases of infection and death tolls, recommends hyper vigilance in daily hygiene such as frequent hand washing or sneezing into the crook of our arms. News reports at all levels, from local school closures to airport screenings and global disease surveillance, continue to remind us of the high risk.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.
› Verified 6 days ago
Madhuri Preeti Rao, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 195 Canal St, Malden, MA 02148 Phone: 781-338-0055 | |
Laura J Sullivan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Canal St, Malden, MA 02148 Phone: 781-338-0500 | |
Ifechukwude Ikem, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 195 Canal St, Malden, MA 02148 Phone: 781-338-0055 | |
Molly B Cohen-osher, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 195 Canal St, Malden, MA 02148 Phone: 781-338-0500 | |
Jennifer Leahy, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Canal St Ste 105, Malden, MA 02148 Phone: 781-338-0055 | |
Cara L Chevalier, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 178 Savin Street, Hallmark Health Medical Associates-family Health Center, Malden, MA 02148 Phone: 781-338-7400 Fax: 781-338-7405 | |
Anna Levit, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 195 Canal St, Malden, MA 02148 Phone: 781-338-0500 |